RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine combo aims to outsmart recurrent ovarian cancer
Disease control Recruiting nowThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRalphaDC) with an immunotherapy drug (pembrolizumab). The goal is to safely boost the immune system to rec…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:23 UTC
-
New drug combo targets tough ovarian cancer
Disease control Recruiting nowThis early-phase trial tests two drugs, abemaciclib and olaparib, together in people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goals are to find the safest dose and see if the combination can shrink tumors. About 42 participants will…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New drug combo trial hopes to tame advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will take …
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests two experimental drugs (M1774 and ZEN-3694) together in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see how well the combination works. About 65 participants will take part to help determine if this…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC